LYNN RUFFOLO: Open Payments
NPI 1083471486 · WINFIELD, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,624 in 95 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $1,847 · 2025 $2,624
Food & beverage: $2,624
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $475 |
| Neurocrine BioSciences, Inc. | 10 | $287 |
| Otsuka America Pharmaceutical, Inc. | 8 | $243 |
| Alkermes, Inc. | 11 | $242 |
| Teva Pharmaceuticals USA, Inc. | 11 | $242 |
| ABBVIE INC. | 11 | $232 |
| Janssen Pharmaceuticals, Inc | 6 | $223 |
| E.R. Squibb & Sons, L.L.C. | 6 | $216 |
| Axsome Therapeutics, Inc. | 6 | $204 |
| Braeburn Inc. | 5 | $117 |
Products named: CAPLYTA, INGREZZA, VRAYLAR, COBENFY, Auvelity, ARISTADA, AUSTEDO XR, ABILIFY ASIMTUFII.
Industry payments across IL — which companies pay providers there.
